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ABSTRACT 
 
Background: Supraglottic airway device (SAD) is a common device use in anaesthesia 
practice including paediatric patients. Air-Q ILA (Cook gas LLC; Mercury Medical, 
Clearwater, FL, USA) is the newer first generation of SAD that can use for both 
primary airway device and an aid for tracheal intubation. Available literature 
demonstrated that this device performed better and equally to the other SAD including 
second generation of SAD. Ambu® AuraGain™ (Ambu, Ballerup, Denmark) is a newer 
second generation of SAD which incorporates both integrating gastric port access and 
intubation capability. The study is conducted to compare the effectiveness between Air-
Q and Ambu AuraGain for controlled ventilation in children up to 30kg. 
Methods: 64 paediatric patients underwent various short surgical procedures were 
randomly assigned to receive either an Air-Q or Ambu AuraGain. Fibreoptic (FO) 
grades of laryngeal view were measured as the primary outcome. The secondary 
outcomes measured were oropharyngeal leak pressure (OLP), number of attempts, time 
of successful insertion, quality of airway during placement and maintenance of 
anaesthesia, haemodynamic parameters and complications. 
Results: Air-Q has more favourable FO grades of view compared to the Ambu 
AuraGain (P = 0.047). OLP is significantly higher in Air-Q group compared to Ambu 
AuraGain (19.41 ± 1.19 cm H20 vs 17.56 ± 1.52 cm H20, P value = <0.001). There were 
no differences in term of number of attempts, time of successful insertion, quality of 
airway during placement and maintenance of anaesthesia and complications. 
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Conclusion: Air-Q offers more clinical advantages than Ambu AuraGain for controlled 
ventilation in paediatric patients as it provides higher airway sealing pressure and better 
FO grade of laryngeal view. 
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ABSTRAK 
 
Latarbelakang: Peranti saluran udara supraglotik (SAD) adalah peranti yang biasa 
digunakan dalam amalan anestesia termasuk pesakit pediatrik. Air-Q ILA (Gas LLC 
Cook; Mercury Medical, Clearwater, FL, USA) merupakan generasi terbaharu SAD 
yang boleh digunakan untuk peranti udara utama dan sebagai bantuan intubasi trakea.  
Sorotan literatur yang ada menunjukkan peranti ini berprestasi lebih baik dan sama 
seperti SAD lain termasuk generasi kedua SAD. Ambu® AuraGain™ (Ambu, Ballerup, 
Denmark) merupakan SAD generasi baru yang menggabungkan kedua-dua port akses 
gastrik dan keupayaan intubasi. Kajian ini diadakan untuk membandingkan 
keberkesanan di antara Air-Q ILA dan Ambu AuraGain untuk ventilasi terkawal dalam 
kalangan kanak-kanak dengan berat sehingga 30 kg. 
Kaedah: 64 pesakit pediatrik yang menjalani pelbagai prosedur pembedahan dipilih 
secara rawak untuk menerima sama ada Air-Q ILA atau Ambu AuraGain. Pandangan 
laringeal dengan Gred optik fiber (FO) diukur sebagai hasil utama. Hasil kedua yang 
diukur adalah kebocoran tekanan orofaringeal (OLP), jumlah percubaan, bilangan 
kemasukan yang berjaya, kualiti aliran udara ketika penempatan dan penyelenggaraan 
anestesia, parameter hemodinamik dan komplikasi. 
Keputusan: Air-Q ILA mempunyai tahap pandangan FO yang lebih baik berbanding 
dengan Ambu AuraGain (P=0.047). OLP lebih tinggi dalam kumpulan Air-Q ILA 
berbanding dengan Ambu AuraGain (19.41±1.19 cm H2O vs 17.56± cm H2O, nilai 
P=<0.001). Tidak terdapat perbezaan daripada segi bilangan percubaan, bilangan 
kemasukan yang berjaya, kualiti aliran udara ketika penempatan dan penyelenggaraan 
anestesia, dan komplikasi. 
x 
 
Kesimpulan: Air-Q ILA menawarkan kelebihan klinikal lebih daripada Ambu 
AuraGain bagi kawalan pengudaraan dalam kalangan pesakit pediatrik kerana ia 
memberi tekanan kedap udara yang lebih tinggi dan tahap pandangan laringeal yang 
lebih baik 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
CHAPTER 1: INTRODUCTION 
1.0 Introduction 
When Archie Brain introduced the first supraglottic airway device (SAD) which was  
the laryngeal mask airway (LMA) in 1983 (1), various types of supraglottic airway 
devices (SADs) started emerging and became an alternative choice of airway 
management in between facemask or tracheal tube (2). SAD is considered more 
invasive than facemask for anaesthesia and less invasive if compared with tracheal 
intubation. SAD defined as a device that delivers oxygen and/or gas without penetrating 
the vocal cords (glottis) (3). This device is designed to maintain clear airway which lies 
outside and creates a seal around the larynx. Therefore the term ―extraglottic‖ maybe 
more accurate but not routinely use (4, 5).  
 
Previously, the roles of SAD are mainly address for routine anaesthesia for low risk 
type of surgery in adult and paediatric populations. However in modern airway 
management, the roles of these devices were extended which include as a conduit for 
tracheal intubation, airway rescue in difficult airway including neonatal resuscitation, 
airway maintenance for obese and higher risk patients and airway management outside 
the operation theatre (6-8).  
 
With so many potential roles in modern airway management, these devices had 
undergone modification and improvement in order to increase safety, functions and 
performances (9-13). Despite of this, there are several limitations related to SAD which 
include stability of the airway, surgical access, ability to ventilate through the device 
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and the risk of pulmonary aspiration and regurgitation (12, 14). According to The 
Fourth National Audit Project of the Royal College of Anaesthetists and Difficult 
Airway Society (NAP4) (15, 16), the major airway complication related to SAD was 
pulmonary aspiration. Therefore the greatest important regarding SAD in anaesthesia 
practice is safety profile rather than efficacy of the device (11, 17). In order to acquire 
the safety data it requires extensive use of the device in thousand patients especially for 
the newer SAD (9, 10).  
 
SADs are widely used in children due to variety of sizes available and successful 
reports used in neonates and patients with airway abnormality (3, 8, 18). When 
choosing the right SAD for paediatric patient, one should consider the paediatric 
anatomy and physiology which differs from adult (5, 19). SAD is relatively easy to 
insert in children. However in infants, the characteristic of epiglottis is long and floppy 
which frequently caught and down folded by the tip of the device (19). Some studies did 
demonstrated the higher incidence of epiglottic downfolding with smaller sizes of SAD 
which confirmed by fibreoptic assessment through the device. But the clinical relation 
to airway obstruction remain unclear (20-22). Other safety concern is gastric 
insufflation during controlled ventilation which common problem in paediatric patients. 
This gas leakage leads to gastric distension which can compromise ventilation and may 
predispose to regurgitation of gastric contents especially in infants.  
 
The established paediatric first generations of SAD were laryngeal mask airway classic 
(cLMA) and laryngeal mask airway Unique (ULMA) and for second generation were 
laryngeal mask airway ProSeal. There were introduced into clinical practice in 1987, 
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1997 and 2000. Among of this, the cLMA have a strong evidence base with more than 
2500 studies supporting their use which then became the benchmark for other SADs 
(10). The cLMA is a first generation without a gastric channel which was introduced in 
clinical practice in 1987. It is made for reusable, has multiple variations and disposable 
variations and the ULMA is the disposable version of cLMA. The limitations of the 
cLMA were leakage during positive pressure ventilation due to moderate pharyngeal 
seal and risk of pulmonary aspiration. This has encouraged modification of device 
which described as second generation of SADs and includes features such as gastric 
drain in order to improve safety. Despite this, more than 70% of anaesthesia practice in 
UK still preferred using first generation of SADs (23). 
 
Air-Q ILA (Cook gas LLC; Mercury Medical, Clearwater, FL, USA) was first 
introduced in 2004 by Dr Daniel Cook.  It is classified as newer first generation of SAD 
available for paediatric population which specifically designed to use as a primary 
airway device and conduit for tracheal intubation. It is available as a single use (Air-Q) 
and reusable (ILA) device. The Air-Q standard cuffed has an oval shape laryngeal mask 
with slightly curved airway tube. It has several numbers of features which include 
shorter shaft, wider airway tube to facilitate tracheal tube either blindly or mounted on 
fibreoptic bronchoscope and detachable connecter. The unique feature of Air-Q is the 
mask has an elevated keyhole-shaped ventilating orifice which designed to prevent 
epiglottic downfolding. The Air-Q had performed well in various pilot (24-26) and 
randomized trial studies in several infants and children (27-30) including several case 
series of difficult airway (31-33).  
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Figure 1: Air-Q ILA (Intubating Laryngeal Airway) with ―keyhole‖ shape mask 
opening to prevent epiglottic downfolding. Image adapted from Hernandez et al 2012. 
 
 
 
Figure 2: Selection of device according to patient weight. Image adapted from product 
information of Air-Q ILA Malaysia 2011. 
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There were slight different in term of range of weight in relation to size of device if 
compared to other SAD.  This new weight-based guidelines had been revised in 2009 by 
Jagannathan (34) after case series use of Air-Q in children with limited mouth opening. 
The potential advantages of Air-Q were ability to provide high leak pressure, superior 
fibreoptic view and can be used for either primary airway maintenance or aid for 
tracheal intubation in difficult airway patients (31-33). A trial compared Air-Q with 
ULMA was found to have higher leak pressure and better fibreoptic view in young 
children (27). Other SADs being compared with Air-Q was Ambu Aura-I (28, 30), 
flexible laryngeal mask airway (fLMA) (29) and LMA ProSeal (25). 
 
Ambu® AuraGain™ (Ambu, Ballerup, Denmark) is a newer second generation of SAD. 
It is the third generation of laryngeal mask from the Ambu A/S manufacturer produced 
in 2015 and recently available in paediatric sizes. Ambu AuraGain is a single use device 
and the only Ambu Aura which designed anatomically curved to follow human airway 
anatomy to ensure rapid insertion. The inflatable mask cuff designed to be thin and soft 
to deliver high seal pressures and wider tube to facilitate tracheal intubation. The 
indication of the device is similar with Air-Q which can be used both as primary airway 
device and aid for tracheal intubation. But the different is this device has integrated 
gastric access channel to facilitate management of gastric contents and prevents gastric 
insufflation.  
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Figure 3: Ambu AuraGain. Image adapted from product information of Ambu AuraGain 
2015. 
 
 
Figure 4: Selection of device according to patient weight. Image adapted from product 
information of Ambu AuraGain 2015. 
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Potential advantages of Ambu AuraGain that need to be highlighted such as ability to 
deliver high sealing pressure, alternative device can be used for primary airway 
maintenance and conduit for tracheal intubation when necessary after device insertion. 
This Ambu AuraGain has limited study in paediatric population. To date, there was only 
one trial comparing Ambu AuraGain with LMA Supreme and this LMA supreme is 
single use SAD with gastric port channel (35). The result of this trial had showed Ambu 
AuraGain have comparable clinical performance with available established second 
generation of SAD.  
 
The introduction of laryngeal mask airway over 30years ago was an important step 
towards development of variety of new SADs. As an anaesthetist, it is worth to 
understand the potential advantages and limitations of each new device which 
introduced into clinical practice through a thorough clinical evaluation compared to the 
device which was already established. This clinical evaluation will help us to provide 
potential benefit to a patient of a specific device according to certain clinical situation. 
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1.2 Study Objectives 
 
1.2.1 General Objective: 
To compare the effectiveness between Air-Q and Ambu AuraGain for controlled 
ventilation in children undergoing elective surgery. 
 
1.2.2 Specific Objectives: 
In order to achieve above general objectives, six specific objectives are formulated: 
1) To compare the ease of insertion (number of attempts and time of 
successful insertion) between Air-Q and Ambu AuraGain for controlled 
ventilation in children undergoing elective surgery. 
2) To compare the oropharyngeal leak pressure (OLP) between Air-Q and 
Ambu AuraGain for controlled ventilation in children undergoing elective 
surgery. 
3) To compare the fibreoptic (FO) grade of laryngeal view between Air-Q 
and Ambu AuraGain for controlled ventilation in children undergoing 
elective surgery. 
4) To compare quality of airway during placement and maintenance of 
anaesthesia between Air-Q and Ambu AuraGain for controlled ventilation 
in children undergoing elective surgery. 
5) To compare the hemodynamic stability (includes BP, MAP, HR and 
spo2) between Air-Q and Ambu AuraGain for controlled ventilation in 
children undergoing elective surgery. 
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6) To compare the incidence of complications between Air-Q and Ambu 
AuraGain for controlled ventilation in children undergoing elective 
surgery. 
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CHAPTER 2: STUDY PROTOCOL 
      2.1 Background of study 
Supraglottic airway devices (SADs) are now become routine in anesthesia practice 
as airway maintenance during low risk surgery, airway rescue in difficult airway, 
conduit to facilitate tracheal intubation and airway management outside operating 
theatre (OT) (1, 2). Many newer SADs are manufactured in the last decade and 
available to anesthetists. The aim is to improve clinical performance, increase safety 
profiles and increase number of functions. Air-Q and Ambu® AuraGain™ is newer 
SADs that can used as primary airway device and also conduit for tracheal 
intubation. With modification of the device and availability of suitable sizes, it has 
increasingly being used in pediatric populations.  
 
Available study showed both of these devices have good clinical performance such 
as higher airway leak pressure and better fibreoptic grades of view. However there is 
no clinical study to date evaluates the clinical performance in between Air-Q and 
Ambu® AuraGain™ in children for primary airway device. Therefore the aim of 
this prospective study is to compare the performance and safety of these two devices 
in terms of OLP (oropharyngeal leak pressure) and fibreoptic grades of view as 
primary outcome. Secondary outcome measures included number of attempts, time 
of insertion, quality of airway during placement and maintenance anesthesia, 
hemodynamic stability and complications. 
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2.2 Literature Review 
Supraglottic airway device (SAD) is the device that can use both in spontaneous and 
ventilated patients during anesthesia (3). It consists of tube that is connected to 
respiratory circuit or breathing bag which is attached to a hypopharyngeal device 
that seals and directs airflow to glottis, trachea and lungs. First generation of SAD is 
a classic laryngeal mask airway (cLMA) which was first invented by Dr Archie 
Brain in 1983 (4) . First used successfully in a pilot study on 23 patients and Dr 
Brain first reported its use in a failed intubation scenario in 1983. It is made from 
silicone, reusable device and act as a benchmark to other SAD. This cLMA become 
commercially available in 1998 and more than 500 British Hospitals used it within 
first 12 months of its availability in the UK. In 1991, the Food and Drug 
Administration of United States approved it as a substitute for face mask during 
elective anesthesia (1). Since then, cLMA has widely used in routine for pediatric 
anesthesia and aid the management of children with difficult airways. 
 
SAD offered advantages over endotracheal intubation as they are easier and faster to 
insert than tracheal tube (5), useful device as rescue in difficult airway (6), better 
hemodynamic stability (7-9) and produce minimal trauma to the airway. In general, 
most common minor adverse effects following SAD is sorethroat and major adverse 
effects, e.g aspiration (10). The Fourth National Audit Project of the Royal College 
of Anesthetists and Difficult Airway Society (NAP4) (11) had highlighted important 
issues around SADs which are the most common complication associated with SAD 
was pulmonary aspiration. Therefore the second generation of SAD have been 
designed to improve performance and increase safety and function by adding 
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esophageal drain channel to reduce risk of aspiration and regurgitation (12, 13) and 
being promoted for routine use in airway management. The most established second 
generation of SAD is ProSeal LMA (pLMA) which was introduced in 2000 and 
pediatric sizes available in 2004 (14). It is designed to use for both spontaneous and 
controlled ventilation. Other newer second generations of SADs that are available in 
all pediatric sizes are I-gel, Supreme LMA (sLMA) and Ambu LMA. For many 
SADs that available, cLMA and pLMA has the largest evidence based on safety and 
efficacy for pediatric population. The others SAD still have lacking data available 
for efficacy and randomized controlled trial needed to establish especially safety 
data.  
 
A survey done in UK (15), majority (>80%) of SADs used in UK pediatric 
anesthetic practice are first generation devices. The reasoning behind were user 
familiarity and cost considerations. The second generation of SADs have been 
slower to adapt due to availability of pediatric sizes which came to market later 
compare to adult and aspiration-related to SAD is seen less frequently and less 
morbidity in children compared with adults (16). 
 
Air-Q ILA (Cook gas LLC; Mercury Medical, Clearwater, FL, USA) is a newer first 
generation of SAD that can use for both primary airway device and conduits for 
tracheal intubation. It is an oval-shaped laryngeal mask with a shortened, wide and 
curved airway tube. Air-Q has three versions which are standard cuffed, self-
pressurized (air-Q SP; lack of an inflatable cuff) and air-Q with an esophageal 
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blocker (second generation device but not yet available for children) and 
manufactured as a reusable or single use device. The Air-Q has number of features 
(17): 
 
 
 
Figure 5: Single use and standard cuffed version of Air-Q. Image adapted from 
Whyte SD et al 2013. 
a) Removable proximal 15mm connector 
b) Larger opening to allow passage of the endotracheal tube 
c) Shorter effective length of the shaft for ease of air-Q removal 
d) Elevated keyhole-shaped ventilating orifice to prevent epiglottic downfolding 
and also shape and orientation of the distal outlet directs a FOB or an 
endotracheal tube towards the glottis 
e) Reinforced bars prevent the tip from downfolding or backfolding 
f) The tab inserted in the pilot balloon valve allows the mask cuff to mould to the 
pharynx,  once the tab is removed, the cuff is seals in its moulded shape 
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Ambu® AuraGain™ (Ambu, Ballerup, Denmark) is a newer second generation of 
SAD and it is Ambu 3
rd
 generation of laryngeal mask which is satisfied 3 
fundamental of airway management such as rapid placement, high seal pressure, 
gastric access channel and intubation capability. Several features are: 
 
    Figure 6: Single use device of Ambu AuraGain. Image adapted from product     
    information of Ambu AuraGain 2015. 
 
a) Gastric drain tube port- for placement of gastric tube  
b) Shorter airway tube and anatomical curve 
c) Soft inflatable cuff for higher pressure 
d) Incorporated bite absorption area 
e) Flat back plate of domen, which creates a stability after placement 
f) Fixation hook for the pilot tube 
 
 
 
e 
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Figure 7: Panel A-D. Images of the size 1.5 Air-Q and size 2 Ambu AuraGain. A)  Lateral views of 
the air-Q (left) and Ambu AuraGain (right). Note the slightly shorter airway tube of Air-Q and larger 
proximity mask of Ambu AuraGain. B) Mask bowls of the Air-Q (left) and Ambu AuraGain (right). 
C) Superior views of the Air-Q (left) and Ambu AuraGain (right). Noted the Ambu AuraGain, the 
gastric drain tube port is located laterally and outside its airway tube and compared with Air-Q has 
no gastric drain tube port. D) Posterior view of the Air-Q (below) and Ambu AuraGain (above). 
Noted the Ambu AuraGain has 2 horizontal markings where the upper incisor/gum line of the patient 
should rest between. Also has additional markings indicates the maximum diameter of tracheal and 
gastric tubes that can fit through the device. For Air-Q, has also 2 similar horizontal markings 
wherethe upper incisor/ gum line of the patient should rest between and the end of airway tube there 
is marking indicates the maximum dianeter of tracheal tube and range of weight. 
 
(d
) 
(b) 
(c) 
(a) 
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Various studies showed satisfactory clinical performance, efficacy and safety of Air-
Q usage as primary airway device and conduit for tracheal intubation in both adult 
and pediatric patients. Available study in children weighing 10-15kg using both first 
generation of SAD as primary airway maintenance found Air-Q have higher airway 
leak pressure and superior fibreoptic (FO) view when compared with LMA-Unique 
(18). Another randomized trial in small infants <10kg also found similar finding 
where cuffed Air-Q is superior compared to flexible laryngeal mask airway (fLMA) 
in providing higher airway sealing pressures and better fibreoptic grade laryngeal 
view (19). When compared with Ambu Aura- I, both devices have similar success 
rate in fibreoptic view but Air-Q provide significant higher airway leak pressure 
(20). In term of ease of insertion and complications there were no difference 
between Air-Q and other first generation SAD. However there is still limited study 
evaluating Air-Q in older pediatrics population. 
 
For Ambu AuraGain in children, available study using sizes 1.5 and 2 found that 
there are comparable clinical performance in between supreme LMA (sLMA) and 
Ambu AuraGain (21). Children receiving LMA supreme required more airway 
maneuvers (7 vs 1 patient, p= 0.06) to maintain airway patency. In view of current 
availability of all pediatric sizes, there are needed another prospective trial to 
evaluate clinical performance of available sizes of the device with other SAD. 
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     2.3 Justification of the study 
The aim of this randomized study is conducted is to evaluate the performance and 
safety of Air-Q as primary airway device in various short surgical procedure in 
children compared to Ambu AuraGain Laryngeal Mask. Current SAD available in 
HUSM is Classic LMA (cLMA), ProSeal LMA (pLMA), Supreme LMA (sLMA) 
and the newer is Ambu AuraGain laryngeal mask. As variety of newer SADs for 
children have emerged since their introduction in clinical practice, hope the 
outcomes of this study it help advancing our knowledge and acumen in selecting 
appropriate devices for pediatric population. 
 
     2.4 Research Objectives 
     The objectives of this study were divided into general and specific objectives. 
 
2.4.1 General Objective 
To compare the effectiveness between Air-Q and Ambu AuraGain for controlled 
ventilation in children undergoing elective surgery. 
2.4.2 Specific Objectives 
1) To compare the ease of insertion (number of attempts and time of 
successful insertion) between Air-Q and Ambu AuraGain for controlled 
ventilation in children undergoing elective surgery. 
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2) To compare the oropharyngeal leak pressure (OLP) between Air-Q and 
Ambu AuraGain for controlled ventilation in children undergoing elective 
surgery. 
3) To compare the fibreoptic (FO) grade of laryngeal view between Air-Q 
and Ambu AuraGain for controlled ventilation in children undergoing 
elective surgery. 
4) To compare quality of airway during placement and maintenance of 
anesthesia between Air-Q and Ambu AuraGain for controlled ventilation 
in children undergoing elective surgery. 
5) To compare the hemodynamic stability (includes BP, MAP, HR and 
spo2) between Air-Q and Ambu AuraGain for controlled ventilation in 
children undergoing elective surgery. 
6) To compare the incidence of complications between Air-Q and Ambu 
AuraGain for controlled ventilation in children undergoing elective 
surgery. 
 
2.5 Null Hypotheses 
1) There is no difference in the ease of insertion (number of attempts and 
time of successful insertion) between Air-Q and Ambu AuraGain for 
controlled ventilation in children undergoing elective surgery. 
2) There is no difference in the oropharyngeal leak pressure (OLP) between 
Air-Q and Ambu AuraGain for controlled ventilation in children 
undergoing elective surgery. 
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3) There is no difference in the fibreoptic (FO) grade of laryngeal view 
between Air-Q and Ambu AuraGain for controlled ventilation in children 
undergoing elective surgery. 
4) There is no difference in the quality of airway during placement and 
maintenance of anesthesia between Air-Q and Ambu AuraGain for 
controlled ventilation in children undergoing elective surgery. 
5) There is no difference in hemodynamic changes (includes BP, HR and 
spo2) between Air-Q and Ambu AuraGain for controlled ventilation in 
children undergoing elective surgery. 
6) There is no difference in the incidence of complications between Air-Q 
and Ambu AuraGain for controlled ventilation in children undergoing 
elective surgery. 
 
2.6. Research Methods and Methodology 
2.6.1 Research Design 
This is a prospective, single blinded and randomized controlled trial study.  
2.6.2 Study Area 
The study will be conducted at General Operation Theatre (GOT), Hospital Universiti 
Sains Malaysia (HUSM). 
2.6.3 Study Population 
Pediatric patients scheduled for various surgical procedures within 2 hours where 
supraglottic airway device (SAD) management would be appropriate. 
